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Drug targets of Nitrogen-bisphosp <p>Growth competition assays using barcoded yeast deletion-mutants reveal the molecular targets of nitrogen containing bisphospho- nates used for the treatment of bone cancers and osteoporosis.</p>
Abstract
Background: Nitrogen-containing bisphosphonates are the elected drugs for the treatment of
diseases in which excessive bone resorption occurs, for example, osteoporosis and cancer-induced
bone diseases. The only known target of nitrogen-containing bisphosphonates is farnesyl
pyrophosphate synthase, which ensures prenylation of prosurvival proteins, such as Ras. However, it
is likely that the action of nitrogen-containing bisphosphonates involves additional unknown
mechanisms. To identify novel targets of nitrogen-containing bisphosphonates, we used a genome-
wide high-throughput screening in which 5,936 Saccharomyces cerevisiae heterozygote barcoded
mutants were grown competitively in the presence of sub-lethal doses of three nitrogen-containing
bisphosphonates (risedronate, alendronate and ibandronate). Strains carrying deletions in genes
encoding potential drug targets show a variation of the intensity of their corresponding barcodes on
the hybridization array over the time.
Results: With this approach, we identified novel targets of nitrogen-containing bisphosphonates,
such as tubulin cofactor B and ASK/DBF4 (Activator of S-phase kinase). The up-regulation of tubulin
cofactor B may explain some previously unknown effects of nitrogen-containing bisphosphonates on
microtubule dynamics and organization. As nitrogen-containing bisphosphonates induce extensive
DNA damage, we also document the role of DBF4 as a key player in nitrogen-containing
bisphosphonate-induced cytotoxicity, thus explaining the effects on the cell-cycle.
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Conclusions: The dataset obtained from the yeast screen was validated in a mammalian system,
allowing the discovery of new biological processes involved in the cellular response to nitrogen-
containing bisphosphonates and opening up opportunities for development of new anticancer drugs.
Background
We exploited the molecular tools available for Saccharomy-
ces cerevisiae to investigate potential targets of the nitrogen-
containing bisphosphonates (N-BPs) alendronate (ALE),
ibandronate (IBA) and risedronate (RIS). N-BPs are pyro-
phosphate analogs used to treat osteoporosis and, at high
doses, cancer-induced bone disease [1]. The primary target of
N-BPs is farnesyl pyrophosphate synthase (FPPS), whose
inhibition prevents protein prenylation [2,3]. In vitro studies
conducted on tumor cell lines suggest that N-BPs are able to
exert a broad spectrum of actions, including inhibition of
invasion, and promotion of cell cycle arrest [1]. However, lit-
tle is known about the molecular mechanisms underlying
these effects. In this context, we performed a large-scale com-
petition experiment with different yeast mutants in the pres-
ence of sub-lethal doses of N-BPs to unravel their secondary
cellular targets and to understand the molecular changes
occurring in cells exposed to such compounds.
The yeast experimental system consists of a collection of
5,936 heterozygote deletant strains encompassing all yeast's
open reading frames (ORFs) [4,5]. Each mutant carries two
molecular barcodes (TAGs), which are 20-bp unique
sequences acting as strain identifiers. The mutants are grown
together in competition under different selective pressures,
and the molecular TAGs are discriminated on a hybridization
array. The strains carrying deletions in genes that are crucial
for the yeast growth in the given conditions will loose the
competition, scored by a progressively lower intensity of their
barcodes on the array over the time. This approach has been
successfully used to functionally characterize all yeast ORFs
[4,5], to identify human genes involved in mitochondrial dis-
eases [6] and to identify drug targets [4,7-9]. Moreover, genes
that are quantitatively important in different environments,
so that, when one allele is missing, the resulting phenotype is
either severely compromised (haploinsufficient) or slightly
favored (haploproficient), can b e  d e t e c t e d  [ 1 0 - 1 3 ] .  I n  o u r
experiment, the haploinsufficient and haploproficient pheno-
types detected in the presence of the N-BPs reveal alleles
whose gene products are affected by the specific condition
and, therefore, likely to be drug targets. With this approach
we confirmed FPPS as the main in vivo target of N-BPs action
and we identified additional biological processes affected by
N-BPs, such as vacuolar acidification, microtubule dynamics,
and DNA replication, underlying the complex cellular effects
that bisphosphonates have on cells.
Results
Competition experiments
The wild type S. cerevisiae strain BY4743 was tested for its
response to ALE, IBA and RIS in order to select a sub-lethal
dose to use with the collection of deletion mutants. RIS and
IBA were powerful growth inhibitors, whereas ALE had a
much weaker effect on the yeast cells (Figure S1 in Additional
data file 1). Competition experiments with 5,936 hemizygous
yeast mutants were carried out in the presence of each drug.
Strains showing a significant change in their growth rate were
identified. The significance threshold was chosen to give a
false discovery rate of q < 0.001 for the haploinsufficient
strains, and of q < 0.01 for the haploproficient ones since only
a smaller number of strains displayed an increase in growth
rate (see Materials and methods; Additional data files 2, 3, 4
and 5). Some strains (197 for RIS, 250 for ALE and 283 for
IBA) were so compromised by N-BPs that they disappeared
from the population after 10 to 12 generations (Additional
data file 2). These strains are referred to as quick disappear-
ing (QD) and, for such mutants, there are no 'growth rate dif-
ference' values.
Lists of strains showing haploinsufficient and haploproficient
profiles in the presence of the drugs are shown in Additional
data file 2 and Additional data file 3, respectively. From these
lists we subsequently removed the strains that carried a
mutation in a dubious ORF (according to the Saccharomyces
Genome Database [14]), those known to harbor erroneous
TAGs [15] and those showing a slow growing phenotype on a
minimal medium (according to the Saccharomyces Genome
Database), since their haploinsufficiency could depend on the
nutrient limiting-medium rather than on the specific drug.
Lists of haploinsufficient and haploproficient strains after the
filtering process are given in Additional data files 4 and 5,
respectively. About 45% of the haploinsufficient strains
(including the QD) overlapped across the three conditions
(Figure 1) and there is a common fingerprint when strain
growth rates are compared between the three conditions (Fig-
ure S2 of the Additional data file 1).
The highest numbers of haploinsufficient and haploproficient
genes were scored in the presence of IBA. The sensitivity and
reliability of the 'barcode' method were demonstrated by the
severe haploinsufficiency, in the presence of RIS and IBA, of
the gene YJL167W, which encodes the yeast farnesyl pyro-
phosphate synthetase Erg20p, the only known molecular tar-
get of N-BPs in humans [16]. Interestingly, ALE, which had
only a very weak effect on S. cerevisiae (Figure S1 in Addi-
tional data file 1), does not seem to compromise the growth
rate of a YJL167W hemizygous mutant, suggesting that itshttp://genomebiology.com/2009/10/9/R93 Genome Biology 2009,     Volume 10, Issue 9, Article R93       Bivi et al. R93.3
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interaction with FPPS is limited or inefficient in yeast. Gene
Ontology analysis applied to the data showed enrichment in
categories such as chromatin remodeling and, more gener-
ally, DNA packaging. A detailed analysis of their human
orthologs revealed the presence of several genes encoding
components of a complex that responds to DNA damage [17],
including  SMARCB1  (yeast  YLR321C),  MCM5  (yeast
YLR274W),  MCM6  (yeast  YGL201C) and DBF4  (yeast
YDR052C). In particular, DBF4 was found to be haploprofi-
cient in the presence of IBA. This was confirmed by growing
separately both a hemizygote DBF4 mutant and the wild-type
strain in the presence and absence of IBA. The results showed
that the DBF4 mutant presents a quantitatively significant
increase in final biomass (P < 6.4 × 10-6; Additional data file
6), suggesting that such a hemizygous mutant can partially
counterbalance the N-BP's toxicity.
Among the strains showing a marked haploinsufficient pro-
file in the presence of the three drugs, we found genes related
t o  p r o t o n  p u m p s ,  w h i c h  w e r e  s u g g e s t e d  a s  N - B P  t a r g e t s
before the discovery of FPPS's involvement [18]. Several reg-
ulators of the plasma membrane H+-ATPase pump PMA1
(encoded by YGL008C  (PMA1)) were highly haploinsuffi-
cient: YDR033W (MRH1; of unknown function), QD in all
three conditions, may be involved in PMA1 regulation accord-
ing to its similarity to HSP30 [19]; YBL069W (AST1), which
plays a role in targeting Pma1p to the membrane [20], is also
haploinsufficient in all three conditions; and YCR024C-A
(PMP1), which encodes a regulatory subunit of PMA1 [21], is
severely haploinsufficient in the presence of IBA. No human
ortholog of MRH1 has been found, although this does not
exclude the possibility of a functional homolog that could rep-
resent a new effector of N-BPs. Several proteins whose func-
tions are linked to microtubules were also significantly
affected by the treatments. The strains hemizygous for ATG11
(YPR049C),  ATG14  (YLR295C) and ATG15  (YCR068W),
whose gene products are involved in autophagy and vacuolar
processing, display a haploinsufficient profile in at least one
of the drug conditions used. Moreover, the deletion mutant
for ATG4 (YNL223W), haploinsufficient in the presence of
RIS, encodes a mediator for the attachment of autophago-
somes to microtubules via its interaction with Tub1p and
Tub2p and has a human homolog, ATG4B. The hemizygous
mutants for alpha-tubulin (TUB3), ADP ribosylation factor
(ARF1) and alpha-tubulin folding protein (ALF1) also show
clear haploinsufficient profiles. In particular, the growth dis-
advantage of ALF1 mutant (YNL148C), homologous to the
mammalian tubulin cofactor B gene (TBCB), was confirmed
by growing individually both the hemizygote mutant and the
wild-type strain in the presence of IBA (quantitatively signif-
icant decrease of final biomass yield, P < 0.0043; Additional
data file 6).
About 135 strains were haploproficient (q < 0.01), and the
most marked phenotypes were those related to the internali-
zation of molecules. For example, RAV1 (YJR033C) encodes
one of the subunits of the RAVE complex responsible for the
assembly of the yeast V-ATPase and vacuolar acidification.
These data indicate that a defect in either the assembly of the
RAVE complex or in the acidification of the vesicles confers
an advantage to the cell in the presence of N-BPs (its human
homolog encodes DmX-like 1 protein). Overall, our data
strongly suggest the involvement of other effectors, besides
FPPS, in N-BP-induced toxicity. The human homologs of the
haploinsufficient and haploproficient genes were studied in
human cell lines to see whether they display similar func-
tions. In particular, since we could identify DNA damage and
cytoskeleton dynamics as the novel processes affected by N-
BP treatment, we focused our attention on genes that consti-
tute fundamental nodes in these processes.
N-BPs induce DNA damage, modulate DBF4 
expression and trafficking and induce cell cycle arrest
N-BP-induced toxicity in S. cerevisiae suggested the possible
involvement of a group of human gene orthologs to those
involved in yeast fitness variation and connected to DNA
damage:  SMARCB1,  MCM5,  MCM6  and  DBF4. Since evi-
Venn diagram of numbers of haploinsufficient and haploproficient genes  after removal of bad tags and dubious ORFs Figure 1
Venn diagram of numbers of haploinsufficient and haploproficient genes 
after removal of bad tags and dubious ORFs. Haploinsufficient genes are 
often shared between all three drug conditions; genes involved in heat 
shock response show a similar phenotype. IBA and ALE appear to have an 
overlapping mode of action on genes associated with secondary N-BP 
targets, such as chromatin structure, but not on primary, mevalonate-
dependent interactions, while RIS and IBA share the main N-BP target, the 
farnesyl transferase ERG20, part of the mevalonate pathway.
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N-BPs induce DNA double-strand breaks Figure 2
N-BPs induce DNA double-strand breaks. MCF-7 cells were treated with 10-4M ALE, IBA and RIS for 72 h. As a positive control, the cells were treated 
with 50 μM etoposide (ETO) for 24 h. Cells were then fixed and stained for γH2A.x (green). Nuclei were visualized by propidium iodide (P.I.) 
counterstaining (red). Scale bar: 4 or 20 μm.
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dence of DNA damage upon N-BP treatment has been
reported after treatment with zoledronic acid [22,23], we
chose to evaluate the formation of DNA double strand breaks
in the presence of ALE, IBA and RIS by measuring the phos-
phorylation status of the histone variant H2A.x (that is,
γH2A.x) [24]. Immunofluorescence microscopy, performed
on MCF-7 cells using a specific antibody directed against
γH2A.x revealed the formation of positive double strand
break foci after treatment with the three N-BPs for 72 h at 10-
4 M (Figure 2). The percentage of cells presenting γH2Ax foci,
evaluated by counting the foci-positive cells on six different
fields in three different experiments was 83 ± 15, 75 ± 14, 75
± 9, and 98 ± 4 in ALE, RIS, IBA and etoposide treated cells,
respectively.
DBF4 is a well known S-phase checkpoint effector [25], and
the DBF4-Cdc7 complex is crucial for the initiation of the
DNA replication by activating the minichromosome mainte-
nance (MCM) protein. Both DBF4-Cdc7 and MCM proteins
are phosphorylated by the protein kinases ATM and ATR
[25]. Cells that are hemizygous for DBF4 are severely hap-
loinsufficient; however, this study shows that such a disad-
vantage is compensated for by the presence of N-BPs,
suggesting the occurrence of epistatic interactions involving
the DBF4 gene. Since DBF4 protein accumulates in the nuclei
of G1-, S-, and M-phase-arrested cells [25], we decided to fol-
low its localization upon N-BP stimulation via immunoblot
analysis of nuclear and cytoplasmic extracts of MCF-7 cells.
Upon stimulation with ALE, RIS and IBA, DBF4 protein accu-
mulates within the nuclear compartment (Figure 3a). These
d a t a  h a v e  a l s o  b e e n  c o n f irmed by immunofluorescence
experiments through confocal analysis, where the presence of
DBF4 in the nuclei of cells treated with N-BPs is particularly
evident in the merged picture (Figure 3b). Interestingly,
DBF4 appeared to have a molecular weight of about 118 kDa,
instead of the nominal 77 kDa, suggesting that a
hyperphosphorylated form of the protein was present in the
cell. This has been confirmed by phosphatase treatment
experiments (data not shown). Flow cytometry analysis after
72 h of 10-4 M N-BP treatment showed that the drugs were
able to block the cell cycle of MCF-7 cells in the S-phase (Fig-
ure S3a in Additional data file 1). In particular, the number of
cycling cells in the S-phase increased from 16% to 21% for
IBA, to 28% for RIS and to 38% for ALE. This observation was
concomitant with a reduction of cells in the G0/G1 phase: 78%
in control cells versus 75%, 64% and 60% in IBA, RIS and
ALE treated cells, respectively. Moreover, the same treatment
led to an increase in the amount of dead cells in the sub-G0/
G1 phase from 13% to 17%, 49% and 58% for IBA, RIS and
ALE, respectively (Figure S3b in Additional data file 1). Nota-
bly, the three drugs showed different potency, with ALE being
the more active both in cell-cycle arrest and in the induction
of cellular death.
DBF4 down-regulation leads to protection from N-BP 
toxicity in MCF-7 cells
As the DBF4 hemizygous yeast strain showed a haploprofi-
cient behavior, the role of its mammalian ortholog DBF4 in
the MCF-7 system was studied by reproducing the conditions
present in the yeast fitness assay. DBF4 protein levels were
down-regulated to about 50% of the normal expression by
using small interfering RNA (siRNA; Figure 4a). The clono-
genic assay showed that mock and control siRNA-transfected
MCF-7 cells, when treated with ALE, displayed a significant
reduction in colony formation in comparison with the
untreated ones. In contrast, colony formation in DBF4-down-
regulated cells was similar to that of the untreated control,
N-BPs modulate DBF4 expression and trafficking Figure 3
N-BPs modulate DBF4 expression and trafficking. MCF-7 cells were 
treated with 10-4 M ALE, RIS and IBA for 72 h, and nuclear and cytoplasmic 
extracts were subjected to SDS-PAGE. (a) Representative western blot 
(WB) analysis of DBF4 expression level; actin was used as loading control 
(Ctrl). (b) MCF-7 cells were fixed and stained for DBF4 (green) after 
stimulation with 10-4 M ALE, RIS or IBA for 48 h. Nuclei were visualized by 
propidium iodide (P.I.) counterstaining (red). Scale bar: 20 μm.
(a)
(b)
WB: DBF4
WB: Actin
Ctrl ALE IBA RIS
Nucleus Cytoplasm
Ctrl ALE IBA RIS
ALE
DBF4 P.I. Merge
RIS
IBA
Ctrl
ALE
DBF4 P.I. Merge
RIS
IBA
Ctrlhttp://genomebiology.com/2009/10/9/R93 Genome Biology 2009,     Volume 10, Issue 9, Article R93       Bivi et al. R93.6
Genome Biology 2009, 10:R93
suggesting protection from the ALE-induced toxicity (Figure
4b).
N-BP effects on microtubules organization and 
dynamics
A group of genes associated with microtubule dynamics
showed a haploinsufficient profile in yeast in the presence of
N-BPs. Among these was ALF1, a homolog of the mammalian
tubulin cofactor B (TBCB) gene, which encodes the α-tubulin
folding protein. It has been demonstrated that changes in
TBCB levels have a strong effect on microtubule growth. In
particular, a recent paper reported that overexpression of
TBCB can lead to microtubule depolymerization in growing
neurites [26]. We therefore evaluated if N-BPs were able to
modify TBCB protein levels in MCF-7 cells. Western blots
were performed on total protein extracts from cells treated
with high doses of N-BPs (10-4 M) for 24, 48 and 72 h, using a
specific antibody directed against TBCB. All three N-BPs used
were able to increase TBCB protein levels and each showed a
peculiar trend of induction, with ALE peaking at 48 h after
stimulation, and RIS and IBA at 24 h after stimulation (Fig-
ure 5a). Electron microscopy on MCF-7 cells showed a
marked effect of N-BPs on protrusions and lamellipodia/filo-
Effect of ALE on the clonogenic growth of DBF4-downregulated MCF-7  cells Figure 4
Effect of ALE on the clonogenic growth of DBF4-downregulated MCF-7 
cells. (a) Endogenous DBF4 protein was downregulated by siRNA. MCF-7 
cells were transfected with only oligofectamine (lane 1, mock), 40 nM 
control siRNA Luciferase GL2 Duplex (lane 2), and 40 nM of siGENOME 
duplex pool directed against DBF4 (lane 3). The total protein extracts 
were subjected to SDS-PAGE and DBF4 protein levels were quantified by 
western blotting (WB) and actin was measured as loading control. Five 
hours after siRNA transfection, MCF-7 cells were subjected to ALE 
treatment at a concentration of 10-6 M for 48 h. (b) Following stimulation, 
1,000 cells were plated for the clonogenic assay. After 10 days, the 
colonies were stained with 10% crystal violet and scored using 
ImageQuant TL computer software. The experiments were performed in 
triplicates and the error bars represent standard error of the mean. Black 
bars represent untreated cells, while stripped bars correspond to DBF4-
downregulated cells. Ctrl, control.
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Effect of N-BPs on microtubule structure Figure 5
Effect of N-BPs on microtubule structure. (a) Effect of N-BP treatment on 
TBCB expression levels. Western blotting (WB) analysis showing the 
protein levels of TBCB after stimulation with 10-4M ALE, RIS and IBA for 
24, 48 and 72 h, respectively. The signal given by total actin was used as a 
loading control (Ctrl). (b) N-BPs disrupt microtubule cytoskeleton 
organization. Ultrastructural pictures of MCF-7 cells under different 
conditions. Left panels: presence of a tightly packed bundle of 
microtubules arranged in a parallel way within a lamellipodial protrusion, 
under basal conditions (original magnifications: × 35,000 (top); × 45,000 
(bottom)). Top right panel: irregular microtubular organization after N-BP 
treatment (10-4 M, 72 h; original magnification × 35,000). Bottom right 
panel: anti-tubulin immunogold labeling of filamentous structures after N-
BP treatment (original magnification × 22,000).
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podia, where the parallel organization of the microtubules
was replaced by a totally irregular one (Figure 5b). Under
basal conditions, the MCF-7 cell cytoplasm showed a system
of regularly arranged microtubules running parallel to each
other, with close bundle formation at the level of lamellipo-
dial protrusions (Figure 5b, top panels). After ALE treatment,
dramatic tubulin involvement was evident since microtubules
were markedly reduced in number and showed structural
alterations such as irregularly wavy course and abrupt break-
downs (Figure 5b, top right). In addition, the concurrent
presence of a lot of filamentous structures together with dec-
oration by colloidal gold particles detectable after anti-tubu-
lin antibody immunogold labeling (Figure 5b, bottom right)
was visible. This completely new finding could be correlated
to the effect that N-BPs have on TBCB. Preliminary experi-
ments with nocodazole [27] suggested that N-BPs may affect
microtubule dynamics (data not shown).
N-BP treatment inhibits cell migration
Based on the finding that N-BPs may have an effect on tubulin
dynamics, which is involved in many essential functions,
including cell movement, we wondered whether N-BP treat-
ment could disturb cell migration. As shown by the time-lapse
microscopy analyses (Figure S4 in Additional data file 1),
while IBA seemed to have only a slight effect, both ALE and,
to higher extent, RIS blocked the migration of MCF-7 cells.
DBF4 and TBCB are differently rescued by 
geranylgeranyl pyrophosphate
The main mechanism of action through which N-BPs block
osteoclast-mediated bone resorption is via FPPS inhibition of
the mevalonate pathway [28]. It has been previously shown
that these drugs inhibit the growth of various cancer cell lines
through a similar mechanism [29,30]. To assess the contribu-
tion of FPPS inhibition on the increase of DBF4 and TBCB
protein levels, we performed rescue experiments with geran-
ylgeranyl pyrophosphate (GGPP) in MCF-7 cells. Cells were
grown with 10-4 M ALE for 48 h and the accumulation of
unprenylated Rap1A was used as a marker for the inhibition
of the pathway [31]. ALE induced an increase in the accumu-
lation of unprenylated Rap1A that was reversed by simultane-
ous addition of 25 μM GGPP (Figure 6). Interestingly, while
the ALE-induced increase of DBF4 was reversed by simulta-
neous addition of 25 μM  o f  G G P P ,  t h e  i n c r e a s e  i n  T B C B
remained unaffected by GGPP treatment, suggesting that dif-
ferent pathways are involved in the N-BP-induced upregula-
tion of DBF4 (mevalonate-dependent) and TBCB
(mevalonate-independent).
Discussion
N-BPs are potent inhibitors of osteoclast-mediated bone
resorption and are used to relieve bone pain and to prevent
skeletal complications in bone metastasis, most common in
breast and prostate cancer [1]. Furthermore, several in vitro
and in vivo studies have reported the ability of N-BPs to exert
a direct anti-tumor effect on cancer cell lines [28]. The actions
of N-BPs on tumor cell lines include the promotion of
apoptosis and the inhibition of cellular adhesion and invasion
[29,30,32]. However, besides the established inhibition of
protein prenylation [16], little is known about other potential
mechanisms involved in N-BP-induced toxicity. In recent
years, with the emerging field of chemogenomics, several
large scale efforts have been made to efficiently identify new
therapeutic targets. In this work we used the 'haploinsuffi-
ciency profiling approach', pioneered in yeast by Giaever and
co-workers [7], in order to identify secondary targets of N-
BPs. S. cerevisiae is very versatile and easily managed and
several high-throughput tools are in place for this it [8].
Moreover, over 30% of human genes involved in diseases
have a homolog in yeast [33], making it an ideal experimental
system to open new promising perspectives for translational
medicine. We carried out a series of competition experiments
with a barcoded collection of 5,936 hemizygous mutants [4,5]
in the presence of ALE, IBA and RIS in order to identify
potential drug targets and gain insight into the molecular
changes occurring in cells exposed to such drugs.
N-BP-induced accumulation of unprenylated Rap1A and increase of DBF4,  but not of TBCB, can be reversed by GGPP Figure 6
N-BP-induced accumulation of unprenylated Rap1A and increase of DBF4, 
but not of TBCB, can be reversed by GGPP. Western blot (WB) analysis 
of MCF-7 cells treated with 10-4 M ALE alone or in combination with 25 
μM GGPP. The same volume of absolute ethanol was used as control 
vehicle of GGPP (Ctrl). Actin was used to show equal loading of the lanes.
WB: TBCB
WB: DBF4
WB: Rap1A
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WB: Actin
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Interestingly, from our study it emerged that several different
molecular players contribute to N-BP-induced toxicity, sug-
gesting that, besides FPPS, which is the primary enzymatic
target and was confirmed by our analysis, there are other
molecules whose functions or expression levels are altered by
the treatment. Moreover, these effectors could help in defin-
ing the exact mechanisms at the root of the different degrees
of potency observed with each N-BP. Notably, some of the tar-
gets we found have already been proposed as molecules
affected by N-BPs. First, in the presence of all three drugs, the
most compromised yeast strains in the competition experi-
ment were the hemizygous mutants for MRH1  and  AST1,
which are related to ATPase-proton pumps. MRH1, as a
homolog of HSP30, has a putative function in the regulation
of the expression of the plasma membrane H+-ATPase pump,
PMA1 [19], while AST1 is responsible for its correct targeting
onto the cell membrane [20]. Furthermore, the product of
PMP1, a small single-span membrane protein that regulates
the H+-ATPase pump [21], was also haploinsufficient with
IBA. Interestingly, the PMA1 hemizygous mutant itself shows
no significant haploinsufficient phenotype, suggesting that
the regulation of this gene, rather than its genome copy
number, is responsible for the pharmacological effects of the
N-BPs. Other genes emerged as a consequence of their
involvement in N-BP uptake or internalization. As an exam-
ple, we found that the RAV1 hemizygous mutant strain is hap-
loproficient when grown in the presence of N-BPs. RAV1
belongs to the RAVE complex, which is responsible for vacu-
olar acidification via the V-ATPase. Recent experiments in
osteoclast cell lines have shown that N-BPs are internalized
via endocytosis and that endosomal acidification is required
for their translocation into the cytoplasm [31]. Our data sup-
port this hypothesis; in fact, a deficiency in the acidification of
the endocytic vesicles preventing the release of the N-BPs into
the cytosol would confer a growth advantage on the cell in the
presence of the drugs.
The 'barcode' technology allowed us to identify two novel bio-
logical processes that appeared to be particularly affected by
the treatments: DNA damage and cytoskeleton dynamics.
DNA damage has been suggested in earlier studies as the
cause of the activation of ATM and ATR after zoledronic acid
stimulation, but clear evidence was still missing for other N-
BPs with different side chains [22,23]. We have demonstrated
for the first time that, in MCF-7 cells, IBA, RIS and ALE are
able to cause a significant accumulation of double strand
breaks. Among the DNA damage-related genes that emerged
from our analysis, we found that encoding the regulatory sub-
unit of the DBF4-Cdc7 complex, which is involved in DNA
replication. In our mammalian model, DNA damage is fol-
lowed by DBF4 phosphorylation and nuclear translocation,
events that we hypothesized to be the triggers of cell cycle
arrest observed in S-phase. Moreover, DBF4 seems to be a key
player in the mechanisms of N-BPs toxicity, since its down-
regulation protected the cells from the anti-proliferative
effect exerted by the N-BPs. In general, this finding opens the
possibility that reverting to a haploproficient phenotype may
constitute a mechanism by which cells become resistant to N-
BPs. The second detected mechanism related to the N-BPs'
effects is microtubules dynamics. In particular, we identified
ALF1, a regulator of alpha-tubulin folding, whose human
homolog is TBCB, as the most interesting gene. In MCF-7
cells, we observed a significant upregulation of TBCB protein
levels after N-BP treatment and the simultaneous loss of
microtubule architecture in sites of active microtubule
assembly, such as protrusions. Therefore, TBCB upregulation
represents a novel mechanism through which N-BPs could
affect cellular viability, and further experiments will be per-
formed to define the effects of N-BPs on microtubule-related
processes, such as mitotic spindle formation and vesicular
transport.
Conclusions
This study has exploited the heterozygous yeast mutant col-
lection for mode-of-action discovery of secondary targets of
N-BPs, the elected drugs for the treatment of bone resorption
and cancer-induced bone diseases [1,34]. In particular, this
work allowed the discovery of two novel biological processes
involved in the cytotoxic effects of the N-BPs, DNA damage
and microtubule assembly, and, thanks to the 'barcode'
approach, these could be linked directly to the responsible
genes, DBF4 and TBCB. In this case, a strong conservation
between yeast and mammalian targets was seen, since their
involvement was confirmed also in our human breast cancer
cell line, MCF-7, used as a mammalian model. Neither DBF4
nor TBCB have been described before as N-BP targets, and
these findings may open up new opportunities for the devel-
opment of new compounds with antitumor activity.
Materials and methods
Chemicals
All the chemicals were from Sigma Aldrich Co. (Milan, Italy)
unless otherwise specified. The GGPP was from American
Radiochemicals Inc. (St Louis, MO, USA), and the bisphos-
phonates were provided by Procter and Gamble Pharmaceu-
ticals (Cincinnati, OH, USA).
Yeast strains and cell lines
The yeast strains used in this work are BY4741 (MATa,
his3Δ1,  leu2Δ0,  met15Δ0,  ura3Δ0), and BY4742 (MATα,
his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0) and BY4743 (MATa/MATα
his3Δ1/his3Δ1 leu2Δ0/leu2Δ0 met15Δ0/MET15 LYS2/lys2Δ0
ura3Δ0/ura3Δ0). The hemizygous deletion collection, in the
diploid BY4743 background, was obtained from the Saccha-
romyces Deletion Consortium [35].
The human breast adenocarcinoma MCF-7 cell line was
obtained from the ATCC collection (Manassas, VA, USA), and
cultured in DMEM. All the yeast media, YPD, SD and F1, were
prepared as described previously [10,36,37]. The hemizygoushttp://genomebiology.com/2009/10/9/R93 Genome Biology 2009,     Volume 10, Issue 9, Article R93       Bivi et al. R93.9
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deletion pool was created manually by growing the strains in
YPD with 15% (v/v) glycerol using 96-well plates, at 30°C
until they reached a stationary phase (48 h). Using a multi-
channel pipette, the mutant strains were combined together
in a sterile Petri dish, before being transferred to a 50 ml Fal-
con tube. The pool was stored at -80°C in 1 ml aliquots.
Competition experiments
To determine the sub-lethal concentrations of the N-BPs, dif-
ferent concentrations of RIS, ALE and IBA were added to cul-
tures of BY4741 and BY4743 grown in F1 medium.
An aliquot (107 cells) of the hemizygote pool was inoculated
into flasks containing 20 ml of YPD medium and allowed to
grow in batch for 18 h at 30°C, with shaking at 170 rpm. The
cells were then diluted to an OD600 of 0.005 in 10 ml of F1
medium containing 5 × 10-4 M RIS, 5 × 10-3 M ALE or 5 × 10-
4 M IBA. To maintain exponential growth, the cells were
allowed to grow for six generations before being diluted back
to an OD600 of 0.02 in fresh F1 medium containing the drugs.
Samples of the cultures were taken throughout the experi-
ment, in particular at the beginning of the competition, just
before adding the drugs (generation 0) and after 10 to 12 and
17 to 20 generations.
Hybridization and statistical analysis
The DNA was extracted from the samples using a DNA tissue
kit (Qiagen, Crawly, West Sussex, UK). The concentration of
the genomic DNA was determined using a Nanodrop (Agilent,
West Lothian, UK) device. The amplifications of the tags and
the hybridization protocol were carried out as described [4].
The arrays were normalized by median centering intensity
values from tags corresponding to mutants, as described [10].
Briefly, log-ratios were calculated between the initial time
point, G0, and subsequent time points, G10 and G20. This
aimed to eliminate tag-specific biases and further normalized
the data. Growth rates were estimated by robust linear regres-
sion on the normalized log-ratios. Type I error rates (P-val-
ues) were estimated by model-based resampling with suitably
re-scaled residuals. False discovery rates (q-values) were esti-
mated according to Benjamini and Hochberg [38]. A q-value
lower <0.001 was set as threshold for a growth rate difference
to be considered statistically significant for haploinsufficient
genes, while q < 0.01 was set as the threshold for haploprofi-
cient genes. Gene Ontology analysis was carried out using
GOMINER on filtered lists of genes [39].
Growth of selected strains on a microplate reader
The strains YDR052C (DBF4) and YNL148C (ALF1) were re-
tested singularly. Accurate growth measurements of the
selected single mutants and the wild-ype parent (BY4743) in
both the presence and absence of IBA were produced using a
Microplate Reader (FLUOstar OPTIMA, BMG Labtech,
Offenburg, Germany). The optical density measurement at
600 nm was taken every 2 minutes for a 24 h period. The
maximum growth rate and final biomass yield were calcu-
lated according to Warringer and Blomberg [40]. Three bio-
logical replicates, each comprising three semi-technical
replicates, were carried out for each mutant strain tested. Two
way ANOVA was carried out for each deletion strain to deter-
mine if there was a significant interaction between the drug
and the deletion strain when compared to the effect of the
drug on the parental background.
Cell cycle analysis
Subconfluent MCF-7 cultures (ATCC), grown in DMEM sup-
plemented with 5% fetal bovine serum (Euroclone Ltd.,
Torquay, UK), 0.1 mM non-essential amino acids and 1 mM
sodium pyruvate, were incubated in the presence or absence
of 10-4 M N-BPs for 72 h and harvested as reported in [41].
Cell cycle distribution was examined by flow cytometry, and
data were analyzed with Cell Quest™ and ModFit LT (FACS-
can, Becton Dickinson, Franklin Lakes, NJ, USA).
Preparation of protein extracts and western blot 
analysis
Cell nuclear extracts were prepared as described previously
[42] and analyzed for protein content (Bio-Rad Protein Assay,
Bio-Rad Laboratories, Muenchen, Germany). To prepare
total protein extracts, cells were lysed in a mild buffer (1% NP-
40, 150 mM NaCl, 10 mM Tris, 2 mM EDTA, pH 7.2); the sus-
pension was then incubated at 4°C for 20 minutes and then
subjected to centrifugation for 20 minutes at 12,000 ×g; the
supernatant was collected and transferred to a new tube as
total extract.
The cellular extracts were electrophoresed and then trans-
ferred to nitrocellulose membranes as previously described
[42]. Blots were incubated with the following polyclonal anti-
bodies: rabbit anti-Dbf4 (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA), rabbit anti-actin (Sigma), goat anti-
Rap1A (C-17 - epitope mapping at the C-terminus of Rap 1A of
human origin), and rabbit anti-Rap1 (121 - epitope mapping
near the C-terminus of Rap 1 of human origin) (Santa Cruz
Biotechnology), and anti-TBCB, a generous gift of JC Zabala,
Universidad de Cantabria, Santander, Spain. The blots were
then incubated with the corresponding peroxidase-conju-
gated anti-serum (Sigma). The bands were quantified as
reported in [41].
Immunofluorescence and confocal microscopy studies
For γH2A.x detection, cells were seeded on slides and the next
day treated with 50 μM etoposide for 24 h (positive control),
10-4 M N-BPs for 72 h or phosphate-buffered saline (control).
Cells were then fixed, blocked and permeabilized as reported
in [41] and incubated with the monoclonal antibody anti-
γH2A.x (clone JBW301, Upstate, Lake Placid, NY, USA) for 2
h. After washing, they were incubated with the secondary
antibody Alexa Fluor 488-conjugated (Molecular Probes Inc.,
Eugene, OR, USA) for 90 minutes. Nuclei were visualized by
1 μg/ml propidium iodide counterstaining.http://genomebiology.com/2009/10/9/R93 Genome Biology 2009,     Volume 10, Issue 9, Article R93       Bivi et al. R93.10
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For DBF4 detection, cells were treated without or with 10-4 M
N-BPs for 72 or 48 h, respectively. Cells were processed as
described with polyclonal anti-Dbf4 antibody for 2 h. After
washing, the cells were incubated with the secondary anti-
body Alexa Fluor 488-conjugated (Molecular Probes) for 90
minutes. Nuclei staining was performed as described above.
The microscope slides were mounted and visualized through
a Leica TCS SP laser-scanning confocal microscope [41].
Time-lapse microscopy
Cells were cultured until reaching confluence, synchronized
for 24 h in the absence of serum, than a wound was created by
scraping the monolayer with a single-edge razor blade. The
cells were then treated or not with 10-4 M N-BPs. Cell migra-
tion was followed for the next 48 h (Leica AF6000 LX), taking
phase-contrast photographs every 4 h.
Electron microscopy and immunogold labeling
Subconfluent cultures of MCF-7 cells were incubated in the
presence or absence of 10-4 M ALE for 72 h. Cells were fixed in
4% glutaraldehyde in 0.1 M phosphate buffer, post-fixed with
2% OsO4 dissolved in the same buffer, and embedded in Epon
812 resin. Thin sections were collected on copper grids with 2
× 1 mm slots and contrasted with uranyl acetate and lead cit-
rate. Observations were made using a Philips CM12 STEM
transmission electron microscope. For immunogold labeling
of tubulin, cells were fixed in neutral buffered 4% paraformal-
dehyde, dehydrated in graded ethanol and embedded in LR-
White resin. Thin sections were collected on nickel grids,
b l o c k e d  w i t h  5 %  n o r m a l  g o a t  serum, and incubated with
1:2,000 diluted mouse anti-tubulin monoclonal antibody, fol-
lowed by diluted 18 nm gold-conjugated anti-mouse second-
ary antibody (Jackson ImmunoResearch Labs, Inc.,
Newmarket, England). After washing, sections were con-
trasted with uranyl acetate and lead citrate. As negative con-
trol, primary antibody was replaced with serum.
RNA interference and clonogenic assay
Dbf4 expression was silenced by using the siGENOME duplex
pool (Dbf4 catalog number MQ-004165-01) as reported [43]
in MCF-7 cells. Control cells were transfected with control oli-
gos (luciferase GL2 duplex, catalog number D001100-01-20).
All the oligos were from Dharmacon Research Inc. (Lafayette,
CO, USA). Transfection mixture was removed after 5 h and
replaced with fresh medium containing 10-6 M alendronate.
After 48 h, cells were collected and counted and Dbf4 protein
levels assessed by western blotting. For the Clonogenic Assay,
1,000 cells were plated in a 60 cm2 petri dish in triplicate;
after 10 days, the colonies were stained with crystal violet
(10% w/v in ethanol 70%; Sigma) and counted using Image-
Quant TL v2003.03 (GE Healthcare, Little Chalfont, Buck-
inghamshire, UK) with 50 cells being the requirement for
scoring as a colony. Relative levels of cell survival were calcu-
lated by comparison with control without drug.
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The following additional data are available with the online
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Additional data file 2). A table listing haploproficient strains
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growth data and two-way ANOVA of the wild-type (WT)
strain and the hemizygote mutants DBF4 (A) and ALF1 (B) in
the presence and absence of the drug ibandronate (IBA)
(Additional data file 6).
Additional data file 1 Figures S1, S2, S3 and S4 Figure S1: wild-type S. cerevisiae responds to the N-BPs in a dose- dependent manner. All three drugs are able to inhibit growth and  equimolar doses of each drug display a different degree of toxicity,  with RIS and IBA being the most powerful. Representative growth  curves of wild-type S. cerevisiae BY4743, grown in the presence of  increasing concentrations of the indicated N-BPs for 20 h. Yeast  growth was monitored using an OD reader with measurements  every 5 minutes. Figure S2: N-BP sensitivity profiling for the signif- icant strains. Each bar in the graph represents a specific strain; the  more negative the value of the bar, the greater the rate of diminu- tion of that strain from the pool. Figure S3: FACS analysis of the  MCF-7 cell line treated with N-BPs. Percentage of cells in G0/G1, S  and G2/M phases (A) after the exclusion of the sub-G1 population  (dead cells), which was analyzed separately (B). Figure S4: effect of  N-BPs on cell migration. MCF-7 cells were treated with or without  100 μM N-BP as described in Materials and methods and observed  by time-lapse microscopy for the next 48 h, taking phase-contrast  photographs every 4 h. The horizontal bars represent the limit of  the slit performed on the cell monolayer at the start of the experi- ment. Five measurements per well were taken; the figure shows a  representative experiment at 24 h and 48 h. Original magnification  200×. Click here for file Additional data file 2 Haploinsufficient strains (q < 0.001) QD strains are shown in red. Click here for file Additional data file 3 Haploproficient strains (q < 0.01) Haploproficient strains (q < 0.01). Click here for file Additional data file 4 Haploinsufficient and QD strains after removal of bad tags Haploinsufficient and QD strains after removal of bad tags. Click here for file Additional data file 5 Haploproficient strains after removal of bad tags Haploproficient strains after removal of bad tags. Click here for file Additional data file 6 Growth data and two-way ANOVA of the wild-type strain and the  hemizygote mutants DBF4 and ALF1 in the presence and absence  of the drug ibandronate Growth data and two-way ANOVA of the wild-type (WT) strain and  the hemizygote mutants DBF4 (A) and ALF1 (B) in the presence  and absence of the drug ibandronate (IBA). Click here for file
Acknowledgements
This work was supported by grants from Procter & Gamble to GT and LM
and from MIUR (FIRB #RBRN07BMCT the Italian Human ProteomeNet) to
GT; DD is sponsored by a NERC Advanced Fellowship.
References
1. Clezardin P, Ebetino FH, Fournier PG: Bisphosphonates and can-
cer-induced bone disease: beyond their antiresorptive
activity.  Cancer Res 2005, 65:4971-4974.
2. Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M,
Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W:
Structural basis for the exceptional in vivo efficacy of
bisphosphonate drugs.  Chem Med Chem 2006, 1:267-273.
3. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers
MJ, Russell RG, Oppermann U: The molecular mechanism of
nitrogen-containing bisphosphonates as antiosteoporosis
drugs.  Proc Natl Acad Sci USA 2006, 103:7829-7834.
4. Winzeler EA, Shoemaker DD, Astromoff A, Liang H, Anderson K,
Andre B, Bangham R, Benito R, Boeke JD, Bussey H, Chu AM, Con-
nelly C, Davis K, Dietrich F, Dow SW, El BM, Foury F, Friend SH,
Gentalen E, Giaever G, Hegemann JH, Jones T, Laub M, Liao H, Lie-
bundguth N, Lockhart DJ, Lucau-Danila A, Lussier M, M'Rabet N,
Menard P, et al.: Functional characterization of the S. cerevisiae
genome by gene deletion and parallel analysis.  Science 1999,
285:901-906.
5. Giaever G, Chu AM, Ni L, Connelly C, Riles L, Veronneau S, Dow S,
Lucau-Danila A, Anderson K, Andre B, Arkin AP, Astromoff A, El-
Bakkoury M, Bangham R, Benito R, Brachat S, Campanaro S, Curtiss
M, Davis K, Deutschbauer A, Entian KD, Flaherty P, Foury F, Garfinkelhttp://genomebiology.com/2009/10/9/R93 Genome Biology 2009,     Volume 10, Issue 9, Article R93       Bivi et al. R93.11
Genome Biology 2009, 10:R93
DJ, Gerstein M, Gotte D, Guldener U, Hegemann JH, Hempel S, Her-
man Z, et al.: Functional profiling of the Saccharomyces cerevi-
siae genome.  Nature 2002, 418:387-391.
6. Steinmetz LM, Scharfe C, Deutschbauer AM, Mokranjac D, Herman
ZS, Jones T, Chu AM, Giaever G, Prokisch H, Oefner PJ, Davis RW:
Systematic screen for human disease genes in yeast.  Nat
Genet 2002, 31:400-404.
7. Giaever G, Shoemaker DD, Jones TW, Liang H, Winzeler EA, Astro-
moff A, Davis RW: Genomic profiling of drug sensitivities via
induced haploinsufficiency.  Nat Genet 1999, 21:278-283.
8. Giaever G, Flaherty P, Kumm J, Proctor M, Nislow C, Jaramillo DF,
Chu AM, Jordan MI, Arkin AP, Davis RW: Chemogenomic profil-
ing: identifying the functional interactions of small molecules
in yeast.  Proc Natl Acad Sci USA 2004, 101:793-798.
9. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS,
Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, Garrett-Engele
P, Rush CM, Bard M, Schimmack G, Phillips JW, Roberts CJ, Shoe-
maker DD: Discovering modes of action for therapeutic com-
pounds using a genome-wide screen of yeast heterozygotes.
Cell 2004, 116:121-137.
10. Delneri D, Hoyle DC, Gkargkas K, Cross EJ, Rash B, Zeef L, Leong
HS, Davey HM, Hayes A, Kell DB, Griffith GW, Oliver SG: Identifi-
cation and characterization of high-flux-control genes of
yeast through competition analyses in continuous cultures.
Nat Genet 2008, 40:113-117.
11. Holland S, Lodwig E, Sideri T, Reader T, Clarke I, Gkargkas K, Hoyle
DC, Delneri D, Oliver SG, Avery SV: Application of the compre-
hensive set of heterozygous yeast deletion mutants to eluci-
date the molecular basis of cellular chromium toxicity.
Genome Biol 2007, 8:R268.
12. Zakrzewska A, Boorsma A, Delneri D, Brul S, Oliver SG, Klis FM:
Cellular processes and pathways that protect Saccharomyces
cerevisiae  cells against the plasma membrane-perturbing
compound chitosan.  Eukaryot Cell 2007, 6:600-608.
13. Deutschbauer AM, Jaramillo DF, Proctor M, Kumm J, Hillenmeyer
ME, Davis RW, Kumm J, Hillenmeyer ME, Davis RW, Nislow C, Giae-
ver G: Mechanisms of haploinsufficiency revealed by genome-
wide profiling in yeast.  Genetics 2005, 169:1915-1925.
14. Saccharomyces  Genome Database   [http://www.yeastge
nome.org/]
15. Eason RG, Pourmand N, Tongprasit W, Herman ZS, Anthony K,
Jejelowo O, Davis RW, Stolc V: Characterization of synthetic
DNA bar codes in Saccharomyces cerevisiae gene-deletion
strains.  Proc Natl Acad Sci USA 2004, 101:11046-11051.
16. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ:
Nitrogen-containing bisphosphonates inhibit the meval-
onate pathway and prevent post-translational prenylation of
GTP-binding proteins, including Ras.  J Bone Miner Res 1998,
13:581-589.
17. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER III, Hurov KE,
Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi
SP, Elledge SJ: ATM and ATR substrate analysis reveals exten-
sive protein networks responsive to DNA damage.  Science
2007, 316:1160-1166.
18. Rodan GA, Fleisch HA: Bisphosphonates: mechanisms of
action.  J Clin Invest 1996, 97:2692-2696.
19. Wu K, Dawe JH, Aris JP: Expression and subcellular localization
of a membrane protein related to Hsp30p in Saccharomyces
cerevisiae.  Biochim Biophys Acta 2000, 1463:477-482.
20. Chang A, Fink GR: Targeting of the yeast plasma membrane
[H+]ATPase: a novel gene AST1 prevents mislocalization of
mutant ATPase to the vacuole.  J Cell Biol 1995, 128:39-49.
21. Navarre C, Ghislain M, Leterme S, Ferroud C, Dufour JP, Goffeau A:
Purification and complete sequence of a small proteolipid
associated with the plasma membrane H(+)-ATPase of Sac-
charomyces cerevisiae.  J Biol Chem 1992, 267:6425-6428.
22. Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D:
Zoledronic acid activates the DNA S-phase checkpoint and
induces osteosarcoma cell death characterized by apoptosis-
inducing factor and endonuclease-G translocation independ-
ently of p53 and retinoblastoma status.  Mol Pharmacol 2007,
71:333-343.
23. Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H,
Ikeda Y, Kizaki M: Zoledronate-induced S phase arrest and
apoptosis accompanied by DNA damage and activation of
the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.
Int J Oncol 2007, 31:285-291.
24. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM: DNA dou-
ble-stranded breaks induce histone H2AX phosphorylation
on serine 139.  J Biol Chem 1998, 273:5858-5868.
25. Cheng L, Collyer T, Hardy CF: Cell cycle regulation of DNA
replication initiator factor Dbf4p.  Mol Cell Biol 1999,
19:4270-4278.
26. Lopez-Fanarraga M, Carranza G, Bellido J, Kortazar D, Villegas JC,
Zabala JC: Tubulin cofactor B plays a role in the neuronal
growth cone.  J Neurochem 2007, 100:1680-1687.
27. Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L:
Nanomolar concentrations of nocodazole alter microtubule
dynamic instability in vivo and  in vitro.  Mol Biol Cell 1997,
8:973-985.
28. van BE, Pieterman E, Cohen L, Lowik C, Papapoulos S: Farnesyl
pyrophosphate synthase is the molecular target of nitrogen-
containing bisphosphonates.  Biochem Biophys Res Commun 1999,
264:108-111.
29. Green JR: Antitumor effects of bisphosphonates.  Cancer 2003,
97(Suppl 3):840-847.
30. Body JJ: Breast cancer: bisphosphonate therapy for meta-
static bone disease.  Clin Cancer Res 2006, 12:6258s-6263s.
31. Thompson K, Rogers MJ, Coxon FP, Crockett JC: Cytosolic entry
of bisphosphonate drugs requires acidification of vesicles
after fluid-phase endocytosis.  Mol Pharmacol 2006,
69:1624-1632.
32. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy
GR, Yoneda T: Bisphosphonate risedronate reduces meta-
static human breast cancer burden in bone in nude mice.
Cancer Res 1995, 55:3551-3557.
33. Foury F: Human genetic diseases: a cross talk between man
and yeast.  Gene 1997, 195:1-10.
34. Papapoulos SE, Eekhoff EM, Zwinderman AH: Acquired resistance
to bisphosphonates in Paget's disease of bone.  J Bone Miner Res
2006, 21(Suppl 2):P88-P91.
35. Saccharomyces  Genome Deletion Project   [http://www-
sequence.stanford.edu/group/yeast_deletion_project/
deletions3.html]
36. Sherman F, Stewart JW, Jackson M, Gilmore RA, Parker JH: Mutants
of yeast defective in iso-1-cytochrome c.  Genetics 1974,
77:255-284.
37. Baganz F, Hayes A, Farquhar R, Butler PR, Gardner DC, Oliver SG:
Quantitative analysis of yeast gene function using competi-
tion experiments in continuous culture.  Yeast 1998,
14:1417-1427.
38. Hochberg Y, Benjamini Y: More powerful procedures for multi-
ple significance testing.  Stat Med 1990, 9:811-818.
39. Zeeberg BR, Feng W, Wang G, Wang MD, Fojo AT, Sunshine M, Nar-
asimhan S, Kane DW, Reinhold WC, Lababidi S, Bussey KJ, Riss J, Bar-
rett JC, Weinstein JN: GoMiner: a resource for biological
interpretation of genomic and proteomic data.  Genome Biol
2003, 4:R28.
40. Warringer J, Blomberg A: Automated screening in
environmental arrays allows analysis of quantitative pheno-
typic profiles in Saccharomyces cerevisiae.  Yeast 2003, 20:53-67.
41. Vascotto C, Fantini D, Romanello M, Cesaratto L, Deganuto M, Leon-
ardi A, Radicella JP, Kelley MR, D'Ambrosio C, Scaloni A, Quadrifoglio
F, Tell G: APE1/Ref-1 interacts with NPM 1 within nucleoli
and plays a role in the rRNA quality control process.  Mol Cell
Biol 2009, 29:1834-1854.
42. Pines A, Perrone L, Bivi N, Romanello M, Damante G, Gulisano M,
Kelley MR, Quadrifoglio F, Tell G: Activation of APE1/Ref-1 is
dependent on reactive oxygen species generated after
purinergic receptor stimulation by ATP.  Nucleic Acids Res 2005,
33:4379-4394.
43. Tenca P, Brotherton D, Montagnoli A, Rainoldi S, Albanese C, Santo-
canale C: C d c 7  i s  a n  a c t i v e  k i n a s e  i n  h u m a n  c a n c e r  c e l l s
undergoing replication stress.  J Biol Chem 2007, 282:208-215.